For immediate release: Wednesday, March 2, 2011
Boston, MA – A new study by Harvard School of Public Health (HSPH) researchers shows that adults who regularly take ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), have about one-third less risk of developing Parkinson’s disease than non-users.
“There is no cure for Parkinson’s disease, so the possibility that ibuprofen, an existing and relatively non-toxic drug, could help protect against the disease is captivating,” said senior author [[Alberto Ascherio]], professor of epidemiology and nutrition at HSPH.
The study will be published online March 2, 2011, in Neurology and is scheduled to appear in the March 8, 2011, print issue.
Parkinson’s disease, a progressive nervous disease occurring generally after age 50, affects at least half a million Americans, according to the National Institute of Neurological Disorders and Stroke. About 50,000 new cases are reported each year, with the number expected to increase as the U.S. population ages. It is hypothesized that ibuprofen may reduce inflammation in the brain that may contribute to the disease.
Prior studies showed a reduced Parkinson’s disease risk among NSAIDS users, but most did not differentiate between ibuprofen and other non-aspirin NSAIDs.
In the new study, Ascherio, lead author Xiang Gao, research scientist at HSPH and associate epidemiologist in the Channing Laboratory at Brigham and Women’s Hospital, and colleagues analyzed data from nearly 99,000 women enrolled in the Brigham and Women’s Hospital-based Nurses’ Health Study and over 37,000 men in the Health Professionals Follow-Up Study. The researchers identified 291 cases (156 men and 135 women) of Parkinson’s disease during their six-year follow-up study (1998-2004 in women; 2000-2006 in men). Based on questionnaires, the researchers analyzed the patients’ use of ibuprofen (e.g. Advil, Motrin, Nuprin), aspirin or aspirin-containing products, other anti-inflammatory pain relievers (e.g., Aleve, Naprosyn), and acetaminophen (e.g., Tylenol). (Although not an NSAID, acetaminophen was included because it’s similarly used to treat pain.) Age, smoking, diet, caffeine, and other variables also were considered.
“We observed that men and women who used ibuprofen two or more times per week were about 38% less likely to develop Parkinson’s disease than those who regularly used aspirin, acetaminophen, or other NSAIDs,” Gao said. “Our findings suggest that ibuprofen could be a potential neuroprotective agent against Parkinson’s disease, however, the exact mechanism is unknown.”
These findings raise hope that a readily available, inexpensive drug could help to treat Parkinson’s disease. “Because the loss of brain cells that leads to Parkinson’s disease occurs over a decade or more, a possible explanation of our findings is that use of ibuprofen protects these cells. If so, use of ibuprofen could help slow the disease’s progression,” Gao said.
The findings do not mean that people who already have Parkinson’s disease should begin taking ibuprofen, Ascherio added. “Although generally perceived as safe, ibuprofen can have side effects, such as increased risk of gastrointestinal bleeding. Whether this risk is compensated by a slowing of the disease progression should be investigated under rigorous supervision in a randomized clinical trial,” he said.
Support for the study was provided by the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke and the Intramural Research Program of NIH’s National Institute of Environmental Health Sciences.
“Use of Ibuprofen and Risk of Parkinson’s Disease,” Xiang Gao, Honglei Chen, Michael A. Schwarzschild, and Alberto Ascherio. Neurology, March 8, 2011. Online March 2, 2011.
For more information:
photo: Kris Snibbe/Harvard Staff Photographer
Harvard School of Public Health (https://www.hsph.harvard.edu) is dedicated to advancing the public’s health through learning, discovery, and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children’s health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit: https://www.hsph.harvard.edu
HSPH on Twitter: http://twitter.com/HarvardHSPH
HSPH on Facebook: http://www.facebook.com/harvardpublichealth
HSPH on You Tube: https://www.youtube.com/user/HarvardPublicHealth
HSPH home page: https://www.hsph.harvard.edu